Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
NEW YORK, Feb. 06, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased DaVita Inc. (NYSE:DVA) securities between August 5, 2015 and October 21, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/davita-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting.
On January 6, 2017, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis.
If you suffered a loss in DaVita you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/davita-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
